Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Jul
08
Today In Oncology
Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies
Addition of Glofitamab to R-CHOP or Pola-R-CHP  in Younger Patients With High-Risk LBCL
Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC
Survey Finds Confusion Over Mammogram Guidelines
Survival Disparities Rise in Patients With Advanced Cancer Depending on Whether They Have Insurance to Cover Immune Checkpoint Inhibitors
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo